<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2018.84069</article-id><article-id pub-id-type="publisher-id">ACM-25611</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20180400000_48677673.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  恶性实体瘤患者外周血T淋巴细胞亚群变化规律与放射性损伤及预后分析及其临床意义
  The Change Rule of Peripheral Blood T Lymphocyte Subsets in Malignant Solid Tumor Patients and Its Clinical Significance in Radioactive Damage and Prognosis Analysis
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>玉婷</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>杨</surname><given-names>杰</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>古丽米拉木</surname><given-names>·艾热提</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>马</surname><given-names>苗苗</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>哈斯也提</surname><given-names>·外里</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>乌鲁木齐市自治区人民医院，新疆 乌鲁木齐</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>05</day><month>06</month><year>2018</year></pub-date><volume>08</volume><issue>04</issue><fpage>408</fpage><lpage>415</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：本文旨在探讨部分实体肿瘤患者T细胞亚群异常变化规律，了解肿瘤患者自身机体的免疫动态，及其与预后及放化疗毒性反应的关系。方法：采用流式细胞技术(FCM)检测并记录94例实体瘤患者放化疗前T淋巴细胞亚群的基线水平，利用相同的技术检测同时期44例正常体检者外周血T淋巴细胞亚群水平。随访6个月以上，观察及评价恶性实体瘤组的预后及放射性损伤情况。结果：1）实体瘤患者放化疗后其T淋巴细胞亚群水平较治疗前基线水平有所下降，差异具有统计学意义；2）放化疗前T淋巴细胞亚群中淋巴细胞总数、CD3总T细胞计数、CD4辅助/诱导T细胞计数与不同预后组(CR, PR, SD, PD)之间存在统计学差异，进一步两两比较显示组间差异仍具有统计学意义；3）合并化疗的实体瘤患者其T淋巴细胞亚群水平较未合并化疗者下降明显，差异具有统计学意义。结论：1）恶性实体肿瘤患者初始治疗前即存在免疫受损；2）放化疗杀伤肿瘤细胞的同时可能导致患者机体免疫功能减低；3）淋巴细胞总数、CD3总T细胞计数、CD4辅助/诱导T细胞计数基线水平低下者其预后较差。
    Objective: The purpose of this paper is to explore T cell subgroup abnormalities in solid tumors patients, comprehend the tumor immune dynamics of cancer patients’ own body, and its rela-tionship with radioactive damage and prognosis. Methods: Using flow cytometry (FCM) technique to measure and record the baseline levels of T lymphocyte subsets of 94 patients with solid tumor before radiation and chemotherapy and using the same technique to detect and record 44 cases healthy people’s peripheral blood T lymphocyte subsets level at the same time, then following up for 6 months or more, observing and evaluating the prognosis and radioactive damage of solid tumor group. Results: T lymphocyte subgroup baseline level had declined in solid tumor patients’ group after radiation and chemotherapy, the difference remained statistically significant (P value &lt; 0.05). There were statistical differences between different prognosis groups (CR, PR, SD, PD) in total number of lymphocyte, CD3 total T cell count and CD4 auxiliary/induction T cell counts level before radiation and chemotherapy and further comparison also showed that the difference remained statistically significant. T lymphocyte subgroup level is decreased in combined chemotherapy patients with solid tumor and meanwhile the difference remained statistically significant. 
  
 
</p></abstract><kwd-group><kwd>恶性实体瘤，肿瘤免疫，T细胞亚群，放射性损伤，预后, Malignant Solid Tumor</kwd><kwd> Tumor Immunity</kwd><kwd> T Cell Subgroup</kwd><kwd> Radiation Damage</kwd><kwd> Prognosis</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>恶性实体瘤患者外周血T淋巴细胞亚群变化 规律与放射性损伤及预后分析及其临床意义<sup> </sup></title><p>王玉婷，杨杰<sup>*</sup>，古丽米拉木&#183;艾热提，马苗苗，哈斯也提&#183;外里</p><p>乌鲁木齐市自治区人民医院，新疆 乌鲁木齐</p><disp-formula id="hanspub.25611-formula82"><graphic xlink:href="//html.hanspub.org/file/7-1570596x5_hanspub.png"  xlink:type="simple"/></disp-formula><p>收稿日期：2018年6月4日；录用日期：2018年6月20日；发布日期：2018年6月27日</p><disp-formula id="hanspub.25611-formula83"><graphic xlink:href="//html.hanspub.org/file/7-1570596x6_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>目的：本文旨在探讨部分实体肿瘤患者T细胞亚群异常变化规律，了解肿瘤患者自身机体的免疫动态，及其与预后及放化疗毒性反应的关系。方法：采用流式细胞技术(FCM)检测并记录94例实体瘤患者放化疗前T淋巴细胞亚群的基线水平，利用相同的技术检测同时期44例正常体检者外周血T淋巴细胞亚群水平。随访6个月以上，观察及评价恶性实体瘤组的预后及放射性损伤情况。结果：1）实体瘤患者放化疗后其T淋巴细胞亚群水平较治疗前基线水平有所下降，差异具有统计学意义；2）放化疗前T淋巴细胞亚群中淋巴细胞总数、CD3总T细胞计数、CD4辅助/诱导T细胞计数与不同预后组(CR, PR, SD, PD)之间存在统计学差异，进一步两两比较显示组间差异仍具有统计学意义；3）合并化疗的实体瘤患者其T淋巴细胞亚群水平较未合并化疗者下降明显，差异具有统计学意义。结论：1）恶性实体肿瘤患者初始治疗前即存在免疫受损；2）放化疗杀伤肿瘤细胞的同时可能导致患者机体免疫功能减低；3）淋巴细胞总数、CD3总T细胞计数、CD4辅助/诱导T细胞计数基线水平低下者其预后较差。</p><p>关键词 :恶性实体瘤，肿瘤免疫，T细胞亚群，放射性损伤，预后</p><disp-formula id="hanspub.25611-formula84"><graphic xlink:href="//html.hanspub.org/file/7-1570596x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2018 by authors and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/7-1570596x8_hanspub.png" /> <img src="//html.hanspub.org/file/7-1570596x9_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>在肿瘤的发生、发展以及抗肿瘤治疗过程中，机体的免疫功能起着重要的作用 [<xref ref-type="bibr" rid="hanspub.25611-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.25611-ref2">2</xref>] 。尤其是T细胞介导的细胞免疫在抗肿瘤免疫中发挥着不容忽视的作用。T细胞亚群是与T细胞介导的细胞免疫有关的重要指标。肿瘤患者的淋巴细胞亚群检测结果可呈异常规律性改变。本临床研究通过检测94例恶性实体肿瘤患者外周血T细胞亚群水平以了解恶性实体肿瘤患者治疗前的初始免疫状态，通过与44例健康对照组比较以观察其异常变化规律，并进一步了解治疗前T细胞亚群水平与预后及放射性损伤反应的关系，探讨其临床意义。</p></sec><sec id="s4"><title>2. 材料与方法</title><sec id="s4_1"><title>2.1. 临床资料</title><p>收集我院自2016年6月至2017年3月首次就诊于我科的恶性实体肿瘤患者，共94例，其中男性26例，女性68例。年龄26岁~86岁，中位年龄53岁；其中汉族48例，其他民族共计46例。其中包括头颈部肿瘤13例、肺癌2例、食管癌3例、下咽癌2例、乳腺癌12例、胃癌3例、直肠癌14例、宫颈癌38例、子宫内膜癌4例、前列腺癌3例，均经病理(包括细胞学或组织学病理)及影像学确诊，所有患者均未经放疗或化疗，无近期急慢性感染史、肝肾功能均正常。全部病例于确诊后抽取外周血检测并记录T细胞亚群的初始水平。同期记录我院体检中心44例正常人(其中女性21例，男性23例，中位年龄50岁；其中汉族28例，其他民族26例)外周血T细胞亚群检测结果。两组观察者经t检验在性别、年龄、民族等方面差异无统计学意义。所有实体瘤患者在结束放化疗后，均随访半年及以上(≥6个月)，分别对放射性损伤及预后进行评价。疗效评价参照RECIST实体瘤疗效评价标准(1.1版)，同时采用放射肿瘤治疗协作组(RTOG)制定的急性放射损伤分级标准对放射性损伤进行评价。所有患者均签署知情同意书并通过伦理审查。</p></sec><sec id="s4_2"><title>2.2. 试剂与仪器</title><p>simulTEslrIMK-lymphocyte试剂盒购自美国BD公司，检测仪器为美国BD公司的FAcs calibur流式细胞仪。</p></sec><sec id="s4_3"><title>2.3. 标本采集与检测</title><p>所有患者均在放化疗前、放化疗后6月抽取外周静脉血2 ml用PE荧光标记的单克隆抗体20 μl加入EDTA抗凝血100 μl发生抗原抗体反应，溶血剂2 ml破坏红细胞，磷酸盐缓冲液洗涤，固定液固定后用流式细胞仪检测并记录外周血T淋巴细胞亚群水平。</p></sec><sec id="s4_4"><title>2.4. 统计学处理</title><p>计量资料以均数&#177;标准差 ( x &#175; &#177; s ) 表示，采用SPSS 25.0统计软件包进行分析，两组样本均数比较采用两独立样本t检验；计数资料采用卡方检验(不满足卡方检验条件时采用Fisher精确概率法)。P &lt; 0.05被认为差异具有统计学意义。</p></sec></sec><sec id="s5"><title>3. 结果</title><sec id="s5_1"><title>3.1. 肿瘤患者外周血T细胞亚群与正常对照组比较</title><p>与正常对照组对比，肿瘤患者外周血淋巴细胞总数、CD3总T细胞计数、CD8抑制/杀伤T细胞计数及CD4<sup>+</sup>/CD8<sup>+</sup>比值均有所下降，且差异具有统计学意义(P &lt; 0.05) (见表1)。</p></sec><sec id="s5_2"><title>3.2. 放化疗前后T淋巴细胞亚群水平的差异性比较</title><p>放化疗后T淋巴细胞亚群不论是在T淋巴细胞亚群正常组及低下组其水平均较放化疗前有所下降，且差异具有统计学意义(P &lt; 0.05) (见表2)。</p></sec><sec id="s5_3"><title>3.3. 放疗前T淋巴细胞亚群水平与放射性损伤分级在化疗组与未化疗组之间的差异性比较</title><p>放疗前T淋巴细胞亚群水平在合并化疗组发生I/II级、III/IV级放射性损伤的风险均较未合并化疗组有所增加，差异具有统计学意义(P &lt; 0.05) (见表3)。</p></sec><sec id="s5_4"><title>3.4. 放化疗前T淋巴细胞亚群水平与不同预后组之间的关系</title><p>放化疗前T淋巴细胞亚群水平CD3、CD4、CD8及CD4<sup>+</sup>/CD8<sup>+</sup>按照正常及低下进行分组(以我院流式细胞仪参数作为参考标准)，分析其各组与不同预后组(CR, PR, SD, PD)之间的关系，因不同预后组为等</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> The difference of peripheral blood T cell subsets between tumor group and control grou</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Groups</th><th align="center" valign="middle" >n</th><th align="center" valign="middle" >Total lymphocyte count</th><th align="center" valign="middle" >CD3<sup>+</sup> count</th><th align="center" valign="middle" >CD4<sup>+</sup> count</th><th align="center" valign="middle" >CD8<sup>+</sup> count</th><th align="center" valign="middle" >CD4/CD8</th></tr></thead><tr><td align="center" valign="middle" >Tumor group</td><td align="center" valign="middle" >182</td><td align="center" valign="middle" >1522.32 &#177; 611.4</td><td align="center" valign="middle" >1043.73 &#177; 490.05</td><td align="center" valign="middle" >554.97 &#177; 311.83</td><td align="center" valign="middle" >473.94 &#177; 275.92</td><td align="center" valign="middle" >1.31 &#177; 0.67</td></tr><tr><td align="center" valign="middle" >control group</td><td align="center" valign="middle" >144</td><td align="center" valign="middle" >1563.95 &#177; 450.99</td><td align="center" valign="middle" >1092.46 &#177; 400.99</td><td align="center" valign="middle" >828.00 &#177; 307.16</td><td align="center" valign="middle" >610.15 &#177; 208.38</td><td align="center" valign="middle" >1.45 &#177; 0.55</td></tr></tbody></table></table-wrap><p>表1. 肿瘤患者外周血T 细胞亚群与正常对照组比较</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> The level of T lymphocyte subgroup differences before and after the radiation therap</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  colspan="2"  >T lymphocyte subgroup level</th><th align="center" valign="middle" >Before n<sub>1</sub></th><th align="center" valign="middle" >After n<sub>2</sub></th><th align="center" valign="middle" >Chi-square value</th><th align="center" valign="middle" >P value</th></tr></thead><tr><td align="center" valign="middle"  rowspan="2"  >Total lymphocyte count</td><td align="center" valign="middle" >Normal group</td><td align="center" valign="middle" >92</td><td align="center" valign="middle" >70</td><td align="center" valign="middle"  rowspan="2"  >484.797</td><td align="center" valign="middle"  rowspan="2"  >0.000</td></tr><tr><td align="center" valign="middle" >Lower group</td><td align="center" valign="middle" >90</td><td align="center" valign="middle" >112</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >CD3<sup>+</sup> count</td><td align="center" valign="middle" >Normal group</td><td align="center" valign="middle" >101</td><td align="center" valign="middle" >74</td><td align="center" valign="middle"  rowspan="2"  >484.808</td><td align="center" valign="middle"  rowspan="2"  >0.000</td></tr><tr><td align="center" valign="middle" >Lower group</td><td align="center" valign="middle" >81</td><td align="center" valign="middle" >108</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >CD4<sup>+</sup> auxiliary/induction T cell counts</td><td align="center" valign="middle" >Normal group</td><td align="center" valign="middle" >120</td><td align="center" valign="middle" >91</td><td align="center" valign="middle"  rowspan="2"  >489.136</td><td align="center" valign="middle"  rowspan="2"  >0.000</td></tr><tr><td align="center" valign="middle" >Lower group</td><td align="center" valign="middle" >62</td><td align="center" valign="middle" >91</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >CD8<sup>+</sup> inhibition/killer T cell count</td><td align="center" valign="middle" >Normal group</td><td align="center" valign="middle" >133</td><td align="center" valign="middle" >98</td><td align="center" valign="middle"  rowspan="2"  >485.005</td><td align="center" valign="middle"  rowspan="2"  >0.000</td></tr><tr><td align="center" valign="middle" >Lower group</td><td align="center" valign="middle" >49</td><td align="center" valign="middle" >84</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >CD4<sup>+</sup>/CD8<sup>+</sup></td><td align="center" valign="middle" >Normal group</td><td align="center" valign="middle" >118</td><td align="center" valign="middle" >104</td><td align="center" valign="middle"  rowspan="2"  >504.611</td><td align="center" valign="middle"  rowspan="2"  >0.000</td></tr><tr><td align="center" valign="middle" >Lower group</td><td align="center" valign="middle" >64</td><td align="center" valign="middle" >78</td></tr></tbody></table></table-wrap><p>表2. 放化疗前后T淋巴细胞亚群水平的差异性比较</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Radioactive damage grade differences in T lymphocyte subgroup level between chemotherapy group and no chemotherapy group before radiation therap</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  colspan="2"   rowspan="2"  >T lymphocyte subgroup level before radiation therapy</th><th align="center" valign="middle"  colspan="4"  >Radioactive damage grade</th></tr></thead><tr><td align="center" valign="middle" >Grade I/II</td><td align="center" valign="middle" >Grade III/IV</td><td align="center" valign="middle" >Chi-square value</td><td align="center" valign="middle" >P value</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >Total lymphocyte count</td><td align="center" valign="middle" >Chemotherapy group n<sub>1</sub> = 77</td><td align="center" valign="middle" >28</td><td align="center" valign="middle" >16</td><td align="center" valign="middle"  rowspan="2"  >149.000</td><td align="center" valign="middle"  rowspan="2"  >0.000</td></tr><tr><td align="center" valign="middle" >No chemotherapy group n<sub>2</sub> = 105</td><td align="center" valign="middle" >61</td><td align="center" valign="middle" >44</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >CD3<sup>+</sup> count</td><td align="center" valign="middle" >Chemotherapy group n<sub>1</sub> = 80</td><td align="center" valign="middle" >43</td><td align="center" valign="middle" >37</td><td align="center" valign="middle"  rowspan="2"  >182.000</td><td align="center" valign="middle"  rowspan="2"  >0.000</td></tr><tr><td align="center" valign="middle" >No chemotherapy group n<sub>2</sub> = 102</td><td align="center" valign="middle" >44</td><td align="center" valign="middle" >58</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >CD4<sup>+</sup> auxiliary/induction T cell counts</td><td align="center" valign="middle" >Chemotherapy group n<sub>1</sub> = 86</td><td align="center" valign="middle" >40</td><td align="center" valign="middle" >46</td><td align="center" valign="middle"  rowspan="2"  >101.758</td><td align="center" valign="middle"  rowspan="2"  >0.000</td></tr><tr><td align="center" valign="middle" >No chemotherapy group n<sub>2</sub> = 96</td><td align="center" valign="middle" >56</td><td align="center" valign="middle" >40</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >CD8<sup>+</sup> inhibition/killer T cell count</td><td align="center" valign="middle" >Chemotherapy group n<sub>1</sub> = 83</td><td align="center" valign="middle" >38</td><td align="center" valign="middle" >45</td><td align="center" valign="middle"  rowspan="2"  >182.000</td><td align="center" valign="middle"  rowspan="2"  >0.000</td></tr><tr><td align="center" valign="middle" >No chemotherapy group n<sub>2</sub> = 99</td><td align="center" valign="middle" >66</td><td align="center" valign="middle" >33</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >CD4<sup>+</sup>/CD8<sup>+</sup></td><td align="center" valign="middle" >Chemotherapy group n<sub>1</sub> = 68</td><td align="center" valign="middle" >36</td><td align="center" valign="middle" >32</td><td align="center" valign="middle"  rowspan="2"  >223.965</td><td align="center" valign="middle"  rowspan="2"  >0.000</td></tr><tr><td align="center" valign="middle" >No chemotherapy group n<sub>2</sub> = 114</td><td align="center" valign="middle" >74</td><td align="center" valign="middle" >40</td></tr></tbody></table></table-wrap><p>表3. 放疗前T淋巴细胞亚群水平与放射性损伤分级在化疗组与未化疗组之间的差异性比较</p><p>级资料，故统计学方法采用两独立样本的非参数检验Mann-Whitney检验，P &lt; 0.05被视为差异具有统计学意义(见表4)。</p><p>表4的统计分析结果初步显示放化疗前T淋巴细胞亚群中淋巴细胞总数、CD3总T细胞计数、CD4辅助/诱导T细胞计数与不同预后组(CR, PR, SD, PD)之间存在统计学差异，故进一步进行组间两两比较(表5、表6、表7)，组间两两比较采用卡方检验，不满足条件时采用Fisher精确概率法(P &lt; 0.01被认为</p><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> The relationship between different prognosis groups with the T lymphocyte subgroup level before chemoradiatio</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  colspan="2"   rowspan="2"  >T lymphocyte subgroup level before chemoradiation therapy</th><th align="center" valign="middle"  colspan="6"  >Different prognosis groups</th></tr></thead><tr><td align="center" valign="middle" >CR</td><td align="center" valign="middle" >PR</td><td align="center" valign="middle" >SD</td><td align="center" valign="middle" >PD</td><td align="center" valign="middle" >Z-value</td><td align="center" valign="middle" >P value</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >Total lymphocyte count</td><td align="center" valign="middle" >Normal group n = 100</td><td align="center" valign="middle" >41</td><td align="center" valign="middle" >27</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >12</td><td align="center" valign="middle"  rowspan="2"  >−3.409</td><td align="center" valign="middle"  rowspan="2"  >0.001</td></tr><tr><td align="center" valign="middle" >Lower group n = 82</td><td align="center" valign="middle" >22</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >30</td><td align="center" valign="middle" >10</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >CD3<sup>+</sup> count</td><td align="center" valign="middle" >Normal group n = 93</td><td align="center" valign="middle" >32</td><td align="center" valign="middle" >28</td><td align="center" valign="middle" >22</td><td align="center" valign="middle" >11</td><td align="center" valign="middle"  rowspan="2"  >−2.991</td><td align="center" valign="middle"  rowspan="2"  >0.003</td></tr><tr><td align="center" valign="middle" >Lower group n = 89</td><td align="center" valign="middle" >29</td><td align="center" valign="middle" >15</td><td align="center" valign="middle" >35</td><td align="center" valign="middle" >10</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >CD4<sup>+</sup> auxiliary/induction T cell counts</td><td align="center" valign="middle" >Normal group n = 109</td><td align="center" valign="middle" >49</td><td align="center" valign="middle" >26</td><td align="center" valign="middle" >24</td><td align="center" valign="middle" >10</td><td align="center" valign="middle"  rowspan="2"  >−5.642</td><td align="center" valign="middle"  rowspan="2"  >0.000</td></tr><tr><td align="center" valign="middle" >Lower group n = 73</td><td align="center" valign="middle" >23</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >28</td><td align="center" valign="middle" >14</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >CD8<sup>+</sup> inhibition/killer T cell count</td><td align="center" valign="middle" >Normal group n = 109</td><td align="center" valign="middle" >49</td><td align="center" valign="middle" >26</td><td align="center" valign="middle" >24</td><td align="center" valign="middle" >10</td><td align="center" valign="middle"  rowspan="2"  >−2.176</td><td align="center" valign="middle"  rowspan="2"  >0.030</td></tr><tr><td align="center" valign="middle" >Lower group n = 73</td><td align="center" valign="middle" >23</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >28</td><td align="center" valign="middle" >14</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >CD4/CD8</td><td align="center" valign="middle" >Normal group n = 104</td><td align="center" valign="middle" >44</td><td align="center" valign="middle" >25</td><td align="center" valign="middle" >23</td><td align="center" valign="middle" >12</td><td align="center" valign="middle"  rowspan="2"  >−0.866</td><td align="center" valign="middle"  rowspan="2"  >0.486</td></tr><tr><td align="center" valign="middle" >Lower group n = 78</td><td align="center" valign="middle" >33</td><td align="center" valign="middle" >15</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >10</td></tr></tbody></table></table-wrap><p>表4. 放化疗前T淋巴细胞亚群水平与不同预后组之间的关系</p><table-wrap id="table5" ><label><xref ref-type="table" rid="table5">Table 5</xref></label><caption><title> The total number of lymphocyte level differences between different prognosis ways before chemoradiatio</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  colspan="2"   rowspan="2"  >Prognosis way</th><th align="center" valign="middle"  colspan="4"  >The lymphatic total</th></tr></thead><tr><td align="center" valign="middle" >Normal group</td><td align="center" valign="middle" >Lower group</td><td align="center" valign="middle" >Chi-square value</td><td align="center" valign="middle" >P value</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >CR/PR</td><td align="center" valign="middle" >CR</td><td align="center" valign="middle" >21</td><td align="center" valign="middle" >12</td><td align="center" valign="middle"  rowspan="2"  >35.092</td><td align="center" valign="middle"  rowspan="2"  >0.000</td></tr><tr><td align="center" valign="middle" >PR</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >10</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >CR/SD</td><td align="center" valign="middle" >CR</td><td align="center" valign="middle" >21</td><td align="center" valign="middle" >12</td><td align="center" valign="middle"  rowspan="2"  >69.624</td><td align="center" valign="middle"  rowspan="2"  >0.000</td></tr><tr><td align="center" valign="middle" >SD</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >20</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >CR/PD</td><td align="center" valign="middle" >CR</td><td align="center" valign="middle" >21</td><td align="center" valign="middle" >12</td><td align="center" valign="middle"  rowspan="2"  >54.978</td><td align="center" valign="middle"  rowspan="2"  >0.000</td></tr><tr><td align="center" valign="middle" >PD</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >10</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >PR/SD</td><td align="center" valign="middle" >PR</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >10</td><td align="center" valign="middle"  rowspan="2"  >26.328</td><td align="center" valign="middle"  rowspan="2"  >0.000</td></tr><tr><td align="center" valign="middle" >SD</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >20</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >PR/PD</td><td align="center" valign="middle" >PR</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >10</td><td align="center" valign="middle"  rowspan="2"  >9.613</td><td align="center" valign="middle"  rowspan="2"  >0.009</td></tr><tr><td align="center" valign="middle" >PD</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >10</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >SD/PD</td><td align="center" valign="middle" >SD</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >20</td><td align="center" valign="middle"  rowspan="2"  >38.132</td><td align="center" valign="middle"  rowspan="2"  >0.000</td></tr><tr><td align="center" valign="middle" >PD</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >10</td></tr></tbody></table></table-wrap><p>表5. 放化疗前淋巴总数水平与不同预后组组间差异性比较</p><table-wrap id="table6" ><label><xref ref-type="table" rid="table6">Table 6</xref></label><caption><title> CD3+ total T cell count differences of between different prognosis ways before chemoradiatio</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  colspan="2"   rowspan="2"  >Prognosis way</th><th align="center" valign="middle"  colspan="4"  >CD3<sup>+</sup> total T cell count</th></tr></thead><tr><td align="center" valign="middle" >Normal group</td><td align="center" valign="middle" >Lower group</td><td align="center" valign="middle" >Chi-square value</td><td align="center" valign="middle" >P value</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >CR/PR</td><td align="center" valign="middle" >CR</td><td align="center" valign="middle" >16</td><td align="center" valign="middle" >8</td><td align="center" valign="middle"  rowspan="2"  >57.247</td><td align="center" valign="middle"  rowspan="2"  >0.000</td></tr><tr><td align="center" valign="middle" >PR</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >10</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >CR/SD</td><td align="center" valign="middle" >CR</td><td align="center" valign="middle" >16</td><td align="center" valign="middle" >8</td><td align="center" valign="middle"  rowspan="2"  >58.927</td><td align="center" valign="middle"  rowspan="2"  >0.000</td></tr><tr><td align="center" valign="middle" >SD</td><td align="center" valign="middle" >9</td><td align="center" valign="middle" >18</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >CR/PD</td><td align="center" valign="middle" >CR</td><td align="center" valign="middle" >16</td><td align="center" valign="middle" >8</td><td align="center" valign="middle"  rowspan="2"  >38.915</td><td align="center" valign="middle"  rowspan="2"  >0.000</td></tr><tr><td align="center" valign="middle" >PD</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >6</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >PR/SD</td><td align="center" valign="middle" >PR</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >10</td><td align="center" valign="middle"  rowspan="2"  >66.801</td><td align="center" valign="middle"  rowspan="2"  >0.000</td></tr><tr><td align="center" valign="middle" >SD</td><td align="center" valign="middle" >9</td><td align="center" valign="middle" >18</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >PR/PD</td><td align="center" valign="middle" >PR</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >10</td><td align="center" valign="middle"  rowspan="2"  >46.181</td><td align="center" valign="middle"  rowspan="2"  >0.000</td></tr><tr><td align="center" valign="middle" >PD</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >6</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >SD/PD</td><td align="center" valign="middle" >SD</td><td align="center" valign="middle" >9</td><td align="center" valign="middle" >18</td><td align="center" valign="middle"  rowspan="2"  >43.359</td><td align="center" valign="middle"  rowspan="2"  >0.000</td></tr><tr><td align="center" valign="middle" >PD</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >6</td></tr></tbody></table></table-wrap><p>表6. 放化疗前CD3总T细胞计数与不同预后组组间差异性比较</p><table-wrap id="table7" ><label><xref ref-type="table" rid="table7">Table 7</xref></label><caption><title> CD4+ auxiliary/induction differences of between different prognosis ways before chemoradiatio</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  colspan="2"   rowspan="2"  >Prognosis way</th><th align="center" valign="middle"  colspan="4"  >CD4<sup>+</sup> auxiliary/induction</th></tr></thead><tr><td align="center" valign="middle" >Normal group</td><td align="center" valign="middle" >Lower group</td><td align="center" valign="middle" >Chi-square value</td><td align="center" valign="middle" >P value</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >CR/PR</td><td align="center" valign="middle" >CR</td><td align="center" valign="middle" >19</td><td align="center" valign="middle" >13</td><td align="center" valign="middle"  rowspan="2"  >60.329</td><td align="center" valign="middle"  rowspan="2"  >0.000</td></tr><tr><td align="center" valign="middle" >PR</td><td align="center" valign="middle" >14</td><td align="center" valign="middle" >8</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >CR/SD</td><td align="center" valign="middle" >CR</td><td align="center" valign="middle" >19</td><td align="center" valign="middle" >13</td><td align="center" valign="middle"  rowspan="2"  >61.646</td><td align="center" valign="middle"  rowspan="2"  >0.000</td></tr><tr><td align="center" valign="middle" >SD</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >10</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >CR/PD</td><td align="center" valign="middle" >CR</td><td align="center" valign="middle" >19</td><td align="center" valign="middle" >13</td><td align="center" valign="middle"  rowspan="2"  >57.669</td><td align="center" valign="middle"  rowspan="2"  >0.000</td></tr><tr><td align="center" valign="middle" >PD</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >14</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >PR/SD</td><td align="center" valign="middle" >PR</td><td align="center" valign="middle" >14</td><td align="center" valign="middle" >8</td><td align="center" valign="middle"  rowspan="2"  >48.345</td><td align="center" valign="middle"  rowspan="2"  >0.000</td></tr><tr><td align="center" valign="middle" >SD</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >10</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >PR/PD</td><td align="center" valign="middle" >PR</td><td align="center" valign="middle" >14</td><td align="center" valign="middle" >8</td><td align="center" valign="middle"  rowspan="2"  >11.901</td><td align="center" valign="middle"  rowspan="2"  >0.001</td></tr><tr><td align="center" valign="middle" >PD</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >14</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >SD/PD</td><td align="center" valign="middle" >SD</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >10</td><td align="center" valign="middle"  rowspan="2"  >43.372</td><td align="center" valign="middle"  rowspan="2"  >0.000</td></tr><tr><td align="center" valign="middle" >PD</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >14</td></tr></tbody></table></table-wrap><p>表7. 放化疗前CD4辅助/诱导T细胞计数与不同预后组组间差异性比较</p><p>差异具有统计学意义)。</p></sec></sec><sec id="s6"><title>4. 讨论</title><p>机体抗肿瘤免疫效应以细胞免疫为主，T淋巴细胞亚群是细胞免疫的主要免疫应答形式，外周血T淋巴细胞亚群能够反映患者的免疫功能，在免疫应答过程中起抗原识别、细胞免疫和免疫调节的作用 [<xref ref-type="bibr" rid="hanspub.25611-ref3">3</xref>] 。在恶性肿瘤的发生和转移过程中，患者机体抗肿瘤免疫中T淋巴细胞(即CD3阳性细胞群体)介导机体的细胞免疫是关键 [<xref ref-type="bibr" rid="hanspub.25611-ref4">4</xref>] ，其细胞功能取决于T淋巴细胞总值(CD<sub>3</sub>)及其亚群的相对组成。T淋巴细胞包括CD4<sup>+</sup>和CD8<sup>+</sup>两个亚群，CD4<sup>+</sup>Th细胞为辅助性T细胞，辅助机体完成抗肿瘤免疫；CD8<sup>+</sup>Ts细胞为抑制性T细胞，抑制机体的免疫应答 [<xref ref-type="bibr" rid="hanspub.25611-ref5">5</xref>] 。在正常情况下以上两类细胞处于动态平衡，正常情况下CD4<sup>+</sup>/CD8<sup>+</sup>比值维持在1.5~2.0之间。若CD4<sup>+</sup>/CD8<sup>+</sup>比值降低，则患者的免疫功能低下，容易引起肿瘤的增殖 [<xref ref-type="bibr" rid="hanspub.25611-ref6">6</xref>] 。通过研究恶性肿瘤患者的外周血T淋巴细胞亚群异常变化规律，可以为恶性肿瘤患者的免疫生物学反应提供相应的参考 [<xref ref-type="bibr" rid="hanspub.25611-ref7">7</xref>] 。当患者免疫功能受抑制或可加速病情的进展 [<xref ref-type="bibr" rid="hanspub.25611-ref8">8</xref>] 。因此，T淋巴细胞亚群检测对肿瘤的预防、诊断和疗后判断均有重要的意义 [<xref ref-type="bibr" rid="hanspub.25611-ref9">9</xref>] [<xref ref-type="bibr" rid="hanspub.25611-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.25611-ref11">11</xref>] 。</p><p>本研究结果显示，与正常对照组相比，肿瘤患者外周血T淋巴细胞亚群有所下降，表现在淋巴细胞总数、CD3总T细胞计数、CD4辅助/诱导T细胞计数、CD8抑制/杀伤T细胞计数及CD4/CD8比值均有所下降，提示肿瘤患者在初始治疗前其细胞免疫状态即存在不同程度的免疫受损。为究其免疫受损状态对放射性损伤及预后的影响，本研究深入比较了放化疗前后淋巴细胞亚群的变化规律，结果揭示放化疗后患者的淋巴细胞亚群较治疗前进一步降低，接受放射治疗且合并化疗者，其后期发生放射性损伤的风险亦有所增加。同时在随访过程中发现淋巴细胞总数、CD3总T细胞计数、CD4辅助/诱导T细胞计数低下者更容易出现病情进展(PD)。大量研究显示辐射能引起胸腺免疫功能长期低下和免疫细胞因子分泌功能失调，本研究与此前的部分研究得出的结论相似，提示经放化疗后细胞免疫功能处于免疫抑制状态，机体对识别和杀伤突变细胞的能力下降，从而导致预后不良。</p><p>化疗被广泛应用于各种实体肿瘤与非实体肿瘤的治疗中，抗肿瘤药物不仅可杀伤肿瘤细胞，也可导致正常细胞受损，而免疫细胞功能与数量减少不利于机体建立抗肿瘤免疫应答 [<xref ref-type="bibr" rid="hanspub.25611-ref12">12</xref>] 。近年来由于肿瘤学、免疫学以及分子生物学等相关学科的理论和技术快速发展和交叉渗透，同时随着对机体抗肿瘤免疫应答的深入了解，以及对肿瘤免疫逃逸机制和肿瘤微环境的深入认识，肿瘤免疫治疗的新策略和新思路已得到进一步的研究和拓展，在实践中其体现出较常规疗法所无可比拟的优势，如对患者器官的损伤小、治疗不良反应小、不易产生耐药、对残存肿瘤细胞的清除更加有效等。因此，动态监测淋巴细胞亚群水平，从经济层面，价格低廉、无创且易于实施；从治疗角度，可了解患者的免疫功能状态，预测放化疗损伤的情况，评估放化疗的疗效，判断肿瘤患者的预后。在患者接受传统的放化治疗期间，增大淋巴细胞总数、CD3总T细胞计数、CD4辅助/诱导T细胞计数、CD4<sup>+</sup>/CD8<sup>+</sup>比值，辅以免疫增强剂以增强患者自身的免疫力，或可使机体自身抗肿瘤免疫效应得到有利发挥，对减少肿瘤复发、转移及减少放化疗损伤的发生都具有重要的临床意义。</p></sec><sec id="s7"><title>基金项目</title><p>新疆维吾尔族自治区青年项目(项目编号：2017D01C148)。</p></sec><sec id="s8"><title>文章引用</title><p>王玉婷,杨 杰,古丽米拉木&#183;艾热提,马苗苗,哈斯也提&#183;外里. 恶性实体瘤患者外周血T淋巴细胞亚群变化规律与放射性损伤及预后分析及其临床意义The Change Rule of Peripheral Blood T Lymphocyte Subsets in Malignant Solid Tumor Patients and Its Clinical Significance in Radioactive Damage and Prognosis Analysis[J]. 临床医学进展, 2018, 08(04): 408-415. https://doi.org/10.12677/ACM.2018.84069</p></sec><sec id="s9"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.25611-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Zamarron, B.F. and Chen, W. (2011) Dual Roles of Immune Cells and Their Factors in Cancer Development and Pro-gression. International Journal of Biological Sciences, 7, 651-658. &lt;br&gt;https://doi.org/10.7150/ijbs.7.651</mixed-citation></ref><ref id="hanspub.25611-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Wormann, S.M., Diakopoulos, K.N., Lesina, M., et al. (2014) The Immune Network in Pancreatic Cancer Development and Progression. Oncogene, 33, 2956-2967. &lt;br&gt;https://doi.org/10.1038/onc.2013.257</mixed-citation></ref><ref id="hanspub.25611-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">时瑛, 李薇. 消化道恶性肿瘤患者外周血免疫细胞的检测[J]. 继续医学教育, 2013, 27(10): 23-24.</mixed-citation></ref><ref id="hanspub.25611-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">江金华, 严汀华, 卢穗万, 等. 外周血Ｔ淋巴细胞亚群与ＮＫ细胞检测在肺癌诊断及治疗中的意义[J]. 肿瘤研究与临床, 2013, 25(2): 90.</mixed-citation></ref><ref id="hanspub.25611-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">陈派强. 外周血T细胞亚群检测在恶性肿瘤中的价值[J]. 医药论坛杂志, 2012, 33(4): 118-119.</mixed-citation></ref><ref id="hanspub.25611-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">任林广, 张健, 徐广伟, 等. 肺癌患者外周血T细胞亚群与NK、NKT细胞检测的临床意义[J]. 中国实验诊断学, 2013, 10(17): 1873-1874.</mixed-citation></ref><ref id="hanspub.25611-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">王道萍, 曹靖. 恶性肿瘤患者医院感染调查及预防对策[J]. 西部医学, 2011, 7(7): 45-47.</mixed-citation></ref><ref id="hanspub.25611-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Ling, K.L., Pratap, S.E., Bates, G.J., et a1. (2007) Increased Frequency of Regulatory T Cells in Peripheral Blood and Turnout Infiltrating Lymphocytes in Colo-rectal Cancer Patients. Cancer Immu., 28, 7-17.</mixed-citation></ref><ref id="hanspub.25611-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Yachida, S., Zhong, Y., Patrascu, R., et al. (2011) Establishment and Characterization of a New Cell Line, A99, from a Primary Small Cell Carcinoma of the Pancreas. Pancreas, 40, 905-910.  
&lt;br&gt;https://doi.org/10.1097/MPA.0b013e3182207a58</mixed-citation></ref><ref id="hanspub.25611-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Sun, J.C., Beilke, J.N. and Lanier, L.L. (2009) Adaptive Immune Features of Natural Killer Cells. Nature, 457, 557-561. &lt;br&gt;https://doi.org/10.1038/nature07665</mixed-citation></ref><ref id="hanspub.25611-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Pan, W.Y., Lo, C.H., Chen, C.C., et al. (2012) Cancer Immunotherapy Using a Membrane-Bound Interleukin-12 with B7-1 Transmbrane and Cytoplasmic Domains. Molecular Therapy, 20, 927-937. &lt;br&gt;https://doi.org/10.1038/mt.2012.10</mixed-citation></ref><ref id="hanspub.25611-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">陈万青, 郑荣寿, 曾红梅, 等. 1989-2008 年中国恶性肿瘤发病趋势分析[J]. 中华肿瘤杂志, 2012, 34(7): 517-524.</mixed-citation></ref></ref-list></back></article>